Pharmacy and therapeutic committees view potential cost savings as the most important factor when recommending formulary placement, according to a new survey.
With rising prescription drug prices challenging payers, how are their key decision makers adjusting their approach to recommending coverage for medicines?
A new survey finds that pharmacy and therapeutic committees, whose job it is to assess the clinical effectiveness of new drugs, view potential cost savings as the most important factor when recommending formulary placement. A formulary is a list of drugs that receive preferred coverage.
On a scale of one to six, potential cost savings of a drug ranked highest, at 3.8. This priority edged out the overall safety and efficacy of a drug relative to directly comparable medicines, at 3.7, according to the survey of P&T committees conducted by Barclays Bank analysts.
Read more at The Wall Street Journal: http://on.wsj.com/1H1vYkb
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Democratic Doctors Caucus Reaffirms EMTALA Amid Trump's CMS Policy Reversal on Abortion Care
June 18th 2025Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient safety.
Read More